Table 4
Effects of GHSR antagonists on glucose and insulin levels.
| Species | Treatment Administration | Dose | Feeding | Measurement blood samples | Plasma glucose levels | Plasma insulin levels | Reference |
| Mice ob/ob | 1 IP GHSR antagonist injection/12 hours versus 1 IP placebo injection | 200โnmol GHRP-6/mouse | Ad libitum SCD | Endpoint 6-day | Diminished | Diminished | [75] |
| Mice ddY | 1 IP GHSR antagonist injection versus 1 IP placebo injection | 10โmol GHRP-6/kg | Fasting overnight | Time course 2 hours | Diminished | Enhanced | | 1 IP GHSR antagonist injection versus 1 IP placebo injection | 1โmol SPA/kg | Fasting overnight | Time course 2 hours | Diminished | Enhanced | [58] | 1 IP GHSR antagonist + ghrelin injection versus 1 IP ghrelin injection | 1โmol GHRP-6/kg +10โnmol ghrelin/kg | Fasting overnight | End point 0.5 hours | Diminished | | |
| Normal rats | 1 IP GHSR antagonist injection versus 1 IP placebo injection | 10โmol GHRP-6/kg | Fasting overnight | End point 0.5 hours | | Enhanced |
[91] | Gastrectomized rats | 1 IP GHSR antagonist injection versus 1 IP placebo injection | 10โmol GHRP-6/kg | Fasting overnight | End point 0.5 hours | | Enhanced |
| Normal rats | Oral GHSR antagonist + IP-GTT versus IP-GTT | 10โmg YIL-781/kg +2โg glucose/kg | Fasting overnight | Time course 6 hours | Diminished | Enhanced |
[92] | Oral GHSR antagonist versus placebo | 30โmg YIL-781/kg | Fasting overnight | Time course 6 hours | Diminished | | DIO rats | Oral GHSR antagonist +IP-GTT versus placebo + IP-GTT | 3โmg YIL-781/kg +2โg glucose/kg | Fasting overnight | Time course 6.5 hours | Diminished | |
|
|